19:22 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Patient sample and mouse studies suggest promoting the interaction of SORL1 with EPHA4 could help treat AD. In frontal cortical tissue samples from postmortem patients, levels of activated EPHA4 -- a...
17:17 , Nov 8, 2017 |  BC Extra  |  Preclinical News

Team identifies new role for SORL1 in Alzheimer's disease

In a paper published in...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

GlaxoSmithKline, Iron Horse Therapeutics neurology news

Avalon Ventures and GlaxoSmithKline launched build-to-buy company Iron Horse Therapeutics with up to $10 million in series A funding and R&D support. The newco is developing small molecule inhibitors of EPH receptor A4 (EPHA4) to...
08:00 , Nov 16, 2015 |  BioCentury  |  Finance

Bigger build-to-buy

An expanded build-to-buy partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will be a cornerstone for Avalon Ventures as it raises its eleventh fund. The pre-arranged exits will make up half of Avalon's life science investments in...
02:49 , Nov 10, 2015 |  BC Extra  |  Financial News

Avalon, GSK launch ALS company Iron Horse

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched build-to-buy company Iron Horse Therapeutics (San Diego, Calif.) with up to $10 million in series A funding and R&D support. The company is developing small molecule inhibitors...
07:00 , Jul 31, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) EPH receptor A4 (EPHA4); b-amyloid (Ab) Mouse studies suggest a small molecule EPHA4 inhibitor could help treat AD. In mouse models of...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Staurosporine analogs (staralogs) with improved selectivity toward analog-sensitive kinases Staralogs could expand approaches to study kinase function using analog-sensitive kinase variants. Kinase variants with genetically...
07:00 , Sep 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) EPH receptor A4 (EPHA4) In vitro and in vivo studies suggest inhibiting EPHA4 could help treat ALS. In a genetic screen...